Article Details

Amgen hands off licensing rights to leprosy, tuberculosis med picked up as part of $13.4B Otezla deal

Retrieved on: 2020-12-23 16:07:30

Tags for this article:

Click the tags to see associated articles and topics

Amgen hands off licensing rights to leprosy, tuberculosis med picked up as part of $13.4B Otezla deal. View article details on hiswai:

Excerpt

Now, Amgen will license that drug to Medicines Development for Global Health, a non-profit biopharma company, and will keep its hands off of any ...

Article found on: endpts.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up